# PT-141 Dosage in the Research Literature: Label Doses, Half-Life, Timing > PT-141 dosage reported as findings only: the bremelanotide label dose (1.75 mg subcutaneous as-needed), Phase 2 dose-finding, half-life ~2.7 h, and timing. Not a protocol for any reader to follow. The doses studied and approved for bremelanotide, with pharmacokinetics and timing — reported as research findings, never as a regimen for any individual to follow. ## Before the details This page reports numbers, it does not prescribe them. The approved bremelanotide product uses a single dose — **1.75 mg injected just under the skin (subcutaneous)**, taken only when needed, capped at one dose per 24 hours and eight per month. Earlier studies tested a few other doses while figuring out where to land. The drug clears from the body fairly quickly (a half-life of roughly 2.7 hours), yet the desire effect was measured for up to 24 hours in a brain-imaging study, because the brain effect outlasts the blood level. Everything below is the label and trial record. It recommends no dose for any person; the approved product is prescription-only, and those decisions belong to a prescriber. ## PT-141 dosage in the research literature Reported as findings only, the **PT-141 dosage** record has a clear center of gravity. The bremelanotide label specifies 1.75 mg subcutaneously, as needed, with no more than one dose per 24 hours and no more than 8 doses per month [6]. Phase 2 subcutaneous dose-finding in women studied 0.75, 1.25, and 1.75 mg before the program settled on 1.75 mg [6]. Two other dosing contexts appear in the literature and should not be confused with the approved regimen. Early intranasal research in men with erectile dysfunction escalated to roughly 7-20 mg, with a statistically significant erectile response above 7 mg, before the intranasal route was discontinued for pharmacokinetic variability [1]. And Phase 1 obesity research in women used subcutaneous doses up to 2.5 mg, up to three times daily for 15 days — a research protocol only, and the source of the weight and caloric-intake observations [7]. These are study and label figures. None is a recommendation. If you are looking for the male-research context specifically, the [PT-141 for men](/pt-141-for-men) page treats the off-label, investigational evidence in full. ## PT-141 dosage for women in the RECONNECT trials For the approved indication, the **PT-141 dosage for women** is the regimen carried by the RECONNECT trials and the label: 1.75 mg subcutaneous, as needed, taken at least 45 minutes before anticipated sexual activity, capped at one dose per 24 hours and 8 per month [6]. That is the exact regimen tested in the two Phase 3 trials that supported approval, across 1,267 premenopausal women with HSDD [3]. This is the approved-product label for premenopausal women with HSDD, reported here as a finding — not a protocol for any reader to follow. The approved product is a prescription pharmaceutical, and dosing decisions belong to a prescriber [6]. ## How long PT-141 lasts: half-life and timing The pharmacokinetics and the felt duration are two different clocks. After subcutaneous administration, median Tmax (time to peak concentration) is about 0.5-1.0 hour, and the terminal half-life is approximately 2.7 hours (range 1.9-4.0 h) per the prescribing information [6]. Early intranasal studies reported a similar half-life of 1.85-2.09 hours [1]. The desire effect, though, outlasts the blood level: in the controlled fMRI study, MC4R agonism increased sexual desire for up to 24 hours [5]. That gap is exactly what a central mechanism predicts — the drug clears, but the circuit effect persists [1]. The label's 45-minute pre-activity timing reflects the onset side of that profile [6]. ## PT-141 half-life The **PT-141 half-life** is approximately 2.7 hours (range 1.9-4.0 h) after subcutaneous administration, per the bremelanotide prescribing information [6]. Supporting pharmacokinetics: volume of distribution about 25.0 L, clearance about 6.5 L/hr, roughly 21% serum protein binding, with excretion 64.8% renal and 22.8% fecal from a radiolabeled dose [6]. Metabolism proceeds by hydrolysis of the cyclic-peptide amide bonds and peptidase digestion, and the cyclic lactam structure confers greater stability than linear melanocortin peptides [1][6]. ## What is the PT-141 dosage? Reported as a finding only: the bremelanotide label specifies 1.75 mg subcutaneously, as needed, with no more than one dose per 24 hours and no more than 8 doses per month [6]. This is the approved-product label, not a protocol for any reader to follow. ## How much PT-141 should I take? This site recommends no dose for any individual. The literature and label report 1.75 mg subcutaneous as-needed for the approved HSDD indication in premenopausal women [6]; the approved product is prescription-only and dosing decisions belong to a prescriber. ## How much PT-141 to inject? The reported label dose is 1.75 mg subcutaneous as-needed [6]; Phase 2 dose-finding studied 0.75, 1.25, and 1.75 mg before settling there [6]. These are study and label figures, not a recommendation, and the approved product is a prepared single-dose autoinjector. ## What is the PT-141 dosage for women? For the approved HSDD indication in premenopausal women, the label specifies 1.75 mg subcutaneous as-needed, taken at least 45 minutes before anticipated activity, capped at one dose per 24 hours and 8 per month [6]. Reported as a finding, not a protocol. ## How do you reconstitute PT-141? The approved product is a prepared single-dose autoinjector, not a reconstituted preparation [6]. Material sold as 'PT-141 research chemical' is for laboratory use only; this site does not provide reconstitution or self-administration instructions and recommends no dose for anyone. ## How do you take PT-141? Per the label, bremelanotide is given subcutaneously (abdomen or thigh) as needed, at least 45 minutes before anticipated sexual activity [6]. Reported here as the approved administration route for the approved indication, not as guidance to self-administer. ## How often can you take PT-141? The label limit is no more than one dose per 24 hours and no more than 8 doses per month [6]. High-frequency dosing appears only in research protocols — for example the Phase 1 obesity studies (up to three times daily) — not the approved regimen [7]. --- A composed printed monograph that sets the PT-141 (bremelanotide) record in order — the one approved indication, the modest measured endpoints, and the nausea-led tolerability cost arranged and cited, with the unverified field reports kept on their own marked sheet; no clinic behind the press and nothing here prescribed, dispensed, or sold.